{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:14:11Z","timestamp":1760181251702,"version":"build-2065373602"},"reference-count":42,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The recent introduction of monoclonal antibodies (MoAbs), with several cellular targets, such as CD-38 (daratumumab and isatuximab) and SLAM F7 (elotuzumab), differently combined with other classes of agents, has significantly extended the outcomes of patients with multiple myeloma (MM) in different phases of the disease. Initially used in advanced\/refractory patients, different MoAbs combination have been introduced in the treatment of newly diagnosed transplant eligible patients (NDTEMM), showing a significant improvement in the depth of the response and in survival outcomes, without a significant price in terms of toxicity. In smoldering MM, MoAbs have been applied, either alone or in combination with other drugs, with the goal of delaying the progression to active MM and restoring the immune system. In this review, we will focus on the main results achieved so far and on the main on-going trials using MoAbs in SMM and NDTEMM.<\/jats:p>","DOI":"10.3390\/ph13120451","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T08:59:34Z","timestamp":1607590774000},"page":"451","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-7305","authenticated-orcid":false,"given":"Elena","family":"Zamagni","sequence":"first","affiliation":[{"name":"Istituto di Ematologia \u201cSeragnoli\u201d, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Tacchetti","sequence":"additional","affiliation":[{"name":"Istituto di Ematologia \u201cSeragnoli\u201d, IRCCS, Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Deias","sequence":"additional","affiliation":[{"name":"Clinica Ematologica e Unit\u00e0 di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[{"name":"Clinica Ematologica e Unit\u00e0 di Terapie Cellulari, Azienda Sanitaria Universitaria Friuli Centrale, 33100 Udine, Italy"},{"name":"Dipartimento di Area Medica, Universit\u00e0 di Udine, 33100 Udine, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,12,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: Changes in early mortality and outcomes in older patients","volume":"28","author":"Dispenzieri","year":"2014","journal-title":"Leukemia"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/bjh.15121","article-title":"Current use of monoclonal antibodies in the treatment of multiple myeloma","volume":"181","author":"Varga","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1080\/14712598.2020.1717464","article-title":"Antibody therapies for multiple myeloma","volume":"20","author":"Gavriatopoulou","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/blood-2014-09-568899","article-title":"Smoldering multiple myeloma","volume":"125","author":"Rajkumar","year":"2015","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/bloodadvances.2018021220","article-title":"Timing of treatment of smoldering myeloma: Early treatment","volume":"2","author":"Mateos","year":"2018","journal-title":"Blood Adv."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of Minimal Residual Disease with Superior Survival Outcomes in Patients with Multiple Myeloma: A Meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: A longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/EDBK_278915","article-title":"The role of early intervention in high-risk smoldering myeloma","volume":"40","author":"Joseph","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/s41375-020-0718-z","article-title":"Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: A randomized, open-label, multicenter, phase 2 study (CENTAURUS)","volume":"34","author":"Landgren","year":"2020","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jamaoncol.2015.2010","article-title":"Treatment with carfilzomib-lenalidomide- dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma","volume":"1","author":"Korde","year":"2015","journal-title":"JAMA Oncol."},{"key":"ref_15","first-page":"402","article-title":"Curative strategy for high-risk smoldering myeloma (GEM-CESAR): Carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd","volume":"130","author":"Mateos","year":"2017","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S1470-2045(16)30124-3","article-title":"Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): Long-term follow-up of a randomised, controlled, phase 3 trial","volume":"17","author":"Mateos","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: Evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Collins","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/bjh.15384","article-title":"Elotuzumab monotherapy in patients with smouldering multiple myeloma: A phase 2 study","volume":"182","author":"Jagannath","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1182\/blood-2018-154","article-title":"Phase 2 trial of combination of elotuzumab, lenalidomide and dexamethasone for high-risk smoldering multiple myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2019.37.15_suppl.8003","article-title":"Efficacy of daratumumab (DARA) + bortezomib\/thalidomide\/dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM) based on minimal residual disease (MRD) status: Analysis of the CASSIOPEIA trial","volume":"37","author":"Moreau","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","article-title":"Evaluation of the Prognostic Value of Positron Emission Tomography-Computer Tomography (PET\/CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia study; Results of the Cassiopet Companion Study","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The Griffin trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Voorhees, P.M., Rodriguez, B., Reeves, B., Nathwani, N., Costa, L.J., Lutska, Y., Hoehn, D., Pei, H., Ukropec, J., and Qi, M. (2018, January 1\u20134). Efficacy and updated safety analysis of a safety run-in cohort from GRIFFIN, a phase 2 randomized study of daratumumab (DARA), bortezomib (V), lenalidomide (R), and dexamethasone (d; DARA-VRd) vs. VRd in patients with newly diagnosed multiple myeloma (NDMM) eligible for high-dose therapy (HDT) and autologous stem cell transplantation (ASCT). Proceedings of the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, San Diego, CA, USA.","DOI":"10.1182\/blood-2018-151"},{"key":"ref_27","first-page":"3110","article-title":"Daratumumab (DARA) in combination with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): Updated results from an Open-Label, Phase 1b Study","volume":"130","author":"Chari","year":"2017","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2019-123170","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (Dara-KRd) induction, autologous transplantation and post-transplant, response-adapted, Measurable Residual Disease (MRD)-based Dara-Krd consolidation in patients with newly diagnosed multiple myeloma (NDMM)","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1182\/blood-2019-126378","article-title":"Weekly carfilzomib, lenalidomide, dexamethasone, daratumumab (wKRd-D) combination therapy provides unprecedented MRD negativity rates in newly diagnosed multiple myeloma: A clinical and correlative phase 2 study","volume":"134","author":"Langdren","year":"2019","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma","volume":"185","author":"Yimer","year":"2019","journal-title":"Br. J. Hematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2020.38.15_suppl.8508","article-title":"Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial","volume":"38","author":"Weisel","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: Elotuzumab plus bortezomib\/dexamethasone vs. bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: A meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Salwender, H., Bertsch, U., Weisel, K., Duerig, J., Kunz, C., Benner, A., Blau, I.W., Raab, M.S., Hillengass, J., and Hose, D. (2019). Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: A randomized phase III trial on the effect of elotuzumab in VRD induction\/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5600-x"},{"key":"ref_37","unstructured":"Goldschmidt, H., Mai, E.K., Salwender, H., Bertsch, U., Miah, K., Kunz, C., Fenk, R., Blau, I., Scheid, C., and Martin, H. (2020). Bortezomib, Lenalidomide and Dexamethasone with or without Elotuzumab as Induction Therapy for Newly-Diagnosed Transplant-Eligible Multiple Myeloma, EHA. Abstract S203."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1182\/blood-2019-130277","article-title":"A phase 2 study to assess the feasibility and tolerance of the combination of elotuzumab, lenalidomide, and dexamethasone (ERd) in the induction, consolidation, and maintenance treatment of transplant-eligible patients newly diagnosed with multiple myeloma (MM)","volume":"134","author":"Berdeja","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.1200\/JCO.2020.38.15_suppl.8507","article-title":"Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with\/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211)","volume":"38","author":"Usmani","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1182\/blood-2019-129504","article-title":"Elotuzumab as post-autologous stem cell transplant consolidation in patients with high-risk myeloma","volume":"134","author":"Gadi","year":"2019","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"102482","DOI":"10.1016\/j.bcmd.2020.102482","article-title":"Elotuzumab-based maintenance therapy following autologous stem cell transplant in multiple myeloma deepens post-transplant responses","volume":"85","author":"Wang","year":"2020","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1200\/EDBK_280221","article-title":"Newly Diagnosed Myeloma in 2020","volume":"40","author":"Moreau","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/12\/451\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:43:05Z","timestamp":1760179385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/12\/451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,10]]},"references-count":42,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["ph13120451"],"URL":"https:\/\/doi.org\/10.3390\/ph13120451","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2020,12,10]]}}}